Medmastery's Cardiology Digest

Welcome to another episode of Medmastery's Cardiology Digest! Today, we're diving into three fascinating studies that have stirred up a bit of chatter in the medical world. So grab your coffee and let's delve right in!

STUDY #1: First, we dig into a study that issues a wake-up call about the potential accuracy of home blood pressure measurements. A dash of detective work is required here that could be the key to solving the mystery of some blood pressure anomalies. Cue suspenseful music!

Picone DS et al. Availability, cost, and consumer ratings of popular nonvalidated vs validated blood pressure–measuring devices sold online in 10 countries. JAMA 2023 May 2; 329:1514. (https://doi.org/10.1001/jama.2023.2661)

STUDY #2: Our second study takes a close look at 24-hour ambulatory blood pressure measurement and its prognostic value. It's a robust study, but doesn't shy away from addressing some thorny issues surrounding the use of ambulatory monitoring in the U.S. Does this comprehensive blood pressure monitoring lead to better clinical outcomes? This is sure to spark some debate!

Staplin N et al. Relationship between clinic and ambulatory blood pressure and mortality: An observational cohort study in 59 124 patients. Lancet 2023 May 5; [e-pub]. (https://doi.org/10.1016/S0140-6736(23)00733-X)

STUDY #3: Lastly, we explore a paper that evaluates whether apixaban, a commonly prescribed oral anticoagulant, had a higher rate of thromboembolic events than warfarin when given to patients with On-X mechanical aortic valves. Tune in as we explore the implications of this eye-opening research!.

Wang TY et al. Apixaban or warfarin in patients with an On-X mechanical aortic valve. NEJM Evid 2023 May 6; [e-pub]. (https://doi.org/10.1056/EVIDoa2300067)

Join us for this informative overview of contemporary research, as we break down complex medical concepts into digestible nuggets of knowledge, suitable for both medical students and healthcare professionals eager to keep up-to-date in cardiology.

For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

Welcome to another enlightening episode of our podcast, where we delve into the latest medical research to bring you insights that can enhance your understanding and practice. This episode focuses on four intriguing studies:

STUDY #1: We begin with a fascinating study comparing the responses of an AI chatbot and physicians to medical questions posted on a Reddit forum. The results might surprise you and prompt a rethink on how AI can assist in routine physician duties.

Ayers JW et al. Comparing physician and artificial intelligence chatbot responses to patient questions posted to a public social media forum. JAMA Intern Med 2023 Apr 28; [e-pub]. (https://doi.org/10.1001/jamainternmed.2023.1838)

STUDY #2: Next, we delve into the POISE-3 trial, which examined the effects of hypotension-avoidance versus hypertension-avoidance strategies in noncardiac surgery. The findings could have significant implications for the management of patients with hypertension undergoing surgery.

Marcucci M et al. Hypotension-avoidance versus hypertension-avoidance strategies in noncardiac surgery: An international randomized controlled trial. Ann Intern Med 2023 Apr 25; 176:605. (https://doi.org/10.7326/M22-3157)

STUDY #3: Our third study is the IRONMAN trial, which investigated the effects of intravenous ferric derisomaltose in patients with heart failure and iron deficiency. The results provide further support for the benefit of iron repletion in this population.

Kalra PR et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022 Dec 17; 400:2199. (https://doi.org/10.1016/S0140-6736(22)02083-9)

STUDY #4: Finally, we discuss a subgroup analysis of the AFFIRM-AHF trial, exploring the association between hemoglobin levels and the efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency. The findings shed light on the role of hemoglobin levels in the treatment outcomes of these patients.

Filippatos G et al. Association between hemoglobin levels and efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency: An AFFIRM-AHF subgroup analysis. Circulation 2023 Apr 13; [e-pub]. (https://doi.org/10.1161/CIRCULATIONAHA.122.060757)

This episode promises to be a treasure trove of knowledge, offering insights into the role of AI in medicine, the management of hypertension in surgery, the importance of iron repletion in heart failure, and the influence of hemoglobin levels on treatment outcomes. So, grab your headphones and join us as we navigate these captivating studies. Don't miss this opportunity to enhance your understanding and make a difference in patients' lives. See you there!

For shownotes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

Welcome to Episode 3 of Medmastery's Cardiology Digest, where we bring you expert insights and the latest scientific findings in the field of cardiology. Stay updated with our bite-sized summaries of late-breaking trials. Hit the subscribe button so you never miss an important update again.

In today's episode, we'll discuss four studies that shed light on new developments in cardiology and medicine:

STUDY 1: The final 15-month results of the MASTER-DAPT trial by Landi A et al. show that abbreviated antiplatelet therapy is non-inferior to standard antiplatelet therapy for high bleeding risk patients undergoing percutaneous coronary intervention (PCI). The trial found that abbreviated therapy significantly reduced the risk of bleeding, with no increase in the risk of ischemic events.

Landi A et al. Abbreviated or standard antiplatelet therapy in HBR patients: Final 15-month results of the MASTER-DAPT trial. JACC Cardiovasc Interv 2023 Apr 10; 16:798. (https://doi.org/10.1016/j.jcin.2023.01.366)

STUDY 2: The prevalence and diagnostic significance of de-novo 12-lead ECG changes after COVID-19 infection in elite soccer players is discussed in a recent study by Bhatia RT et al. The study found that over 20% of the players had de-novo ECG changes, which were associated with myocardial inflammation and fibrosis. The authors recommend routine ECG screening for athletes post-COVID-19 infection.

Bhatia RT et al. Prevalence and diagnostic significance of de-novo 12-lead ECG changes after COVID-19 infection in elite soccer players. Heart 2023 Mar 27; [e-pub]. (https://doi.org/10.1136/heartjnl-2022-322211)

STUDY 3: Haupt CE and Marks M discuss the benefits, limits, and risks of AI-generated medical advice in their recent JAMA article. They argue that AI-generated advice has the potential to improve clinical decision-making and reduce errors, but highlight the need for appropriate training, validation, and regulation to ensure patient safety.

Haupt CE, Marks M. AI-Generated Medical Advice-GPT and Beyond. JAMA. 2023 Apr 25;329(16):1349-1350. doi: 10.1001/jama.2023.5321. PMID: 36972070.

Study 4: Lee P et al. discuss the benefits, limits, and risks of GPT-4 as an AI chatbot for medicine in their recent NEJM article. They note that while GPT-4 has the potential to improve patient education and communication, it also raises concerns around privacy, liability, and bias. The authors highlight the need for further research and guidelines on the use of AI chatbots in healthcare.

Lee P, Bubeck S, Petro J. Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine. N Engl J Med. 2023 Mar 30;388(13):1233-1239. doi: 10.1056/NEJMsr2214184. PMID: 36988602.

Thanks for listening to Medmastery's Cardiology Digest. Join us next week for more expert insights and scientific updates and visit https://www.medmastery.com/podcasts/cardiology-podcast for more information.

We've got an amazing podcast episode lined up for you that'll surely quench your thirst for knowledge on cardiovascular health.

In this episode, we dive deep into four intriguing studies:

STUDY #1: First, we'll explore how the Mediterranean diet can work wonders for your heart, and how a simple low-fat diet may offer similar benefits. Can both diets really reduce mortality in patients at increased risk? Tune in to find out!

Karam G et al. Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: Systematic review and network meta-analysis. BMJ 2023 Mar 29; 380:e072003. (https://doi.org/10.1136/bmj-2022-072003)

STUDY #2: Next, we'll unravel the mystery behind the low statin use for primary prevention of ASCVD among all race and ethnicity groups, with Black and Hispanic adults being the least likely to receive them. Why is this happening, and what can we do about it? 💊

Jacobs JA et al. Prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease by race, ethnicity, and 10-year disease risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol 2023 Mar 22; [e-pub]. (https://doi.org/10.1001/jamacardio.2023.0228)

STUDY #3: Third, we'll talk about a meta-analysis that redefines which patients benefit from CRT and which don't. Brace yourself for some practice-changing revelations as we discuss LBBB, IVCD, and the magic number: 150 ms QRS duration. ⚡

Friedman DJ et al. Cardiac resynchronization therapy improves outcomes in patients with intraventricular conduction delay but not right bundle branch block: A patient-level meta-analysis of randomized controlled trials. Circulation 2023 Mar 7; 147:812. (https://doi.org/10.1161/CIRCULATIONAHA.122.062124)

STUDY #4: Lastly, we'll touch on the alarming decline in U.S. life expectancy, especially for young and middle-aged adults. Heart disease is on the rise, and it's high time we focus on preventing cardiovascular disease (CVD) early in life. 🚨

Aggarwal R et al. Cardiovascular risk factor prevalence, treatment, and control in US Adults aged 20 to 44 years, 2009 to Mar 2020. JAMA 2023 Mar 5; [e-pub]. (https://doi.org/10.1001/jama.2023.2307)

This episode is a treasure trove of knowledge and insights into cardiovascular health. So grab your headphones and get ready to be enlightened! Join us as we navigate these captivating studies and uncover the secrets to a healthier heart. Don't miss this opportunity to enhance your understanding and make a difference in patients' lives. See you there!

For shownotes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

Welcome to another exciting podcast episode, where we dive into the latest cardiovascular research!

Join us as we discuss four fascinating studies:

STUDY #1: Discover how subclinical coronary atherosclerosis detected by computed tomographic angiography (CTA) can pose a significant risk for myocardial infarction (MI) in asymptomatic middle-aged men and women in a Danish cohort.

Fuchs A et al. Subclinical coronary atherosclerosis and risk for myocardial infarction in a Danish cohort: A prospective observational cohort study. Ann Intern Med 2023 Mar 28; [e-pub]. (https://doi.org/10.7326/M22-3027)

STUDY #2: We'll examine the Open Payments Program (OPP) data, revealing trends in industry payments to cardiologists from 2014 to 2019, including the necessity for transparency.

Zhang R et al. Trends in industry payments to cardiologists from 2014 to 2019. Circ Cardiovasc Qual Outcomes 2023 Mar 17; [e-pub]. (https://doi.org/10.1161/CIRCOUTCOMES.122.009820)

STUDY #3: In this randomized case-crossover study, we'll explore whether caffeinated coffee affects premature atrial contractions (PACs) and ventricular contractions (PVCs) in healthy adults.

Marcus GM et al. Acute effects of coffee consumption on health among ambulatory adults. N Engl J Med 2023 Mar 23; 388:1092. (https://doi.org/10.1056/NEJMoa2204737)

STUDY #4: Lastly, we'll discuss a phase 3 trial of sotatercept, a potential new class of therapy for pulmonary arterial hypertension (PAH), focusing on its effects on 6-minute walk distance and other secondary endpoints.

Hoeper MM et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 2023 Mar 6; [e-pub]. (https://doi.org/10.1056/NEJMoa2213558)

This episode promises to be a wealth of knowledge and insights into cardiovascular health. So, get comfortable, grab your headphones, and let's dive into these captivating studies to uncover the secrets to a healthier heart. Enhance your understanding and make a difference in patients' lives. See you there!

For shownotes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.